Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models (Scientific Reports, (2019), 9, 1, (10898), 10.1038/s41598-019-45319-4)

This Article contains errors. As a result of a Figure assembly error, in Figure 5B the image for ABC-16TX1 control is a duplicate of the image for ABC-16TX1 with Everolimus. The correct Figure 5 is included below as Figure 1. The legend of Supplementary Figure 2, “Cell proliferation situations under the 200 nM everolimus treatment alone after 24 hours.” Should read: “Cell proliferation situations under the 200 nM everolimus treatment alone after about 24 hours.” The legend of Supplementary Figure 4 “The resultant IF intensity from the combined labeling of the two antibodies clearly showed efficacy of administrating everolimus.” Should read: “The resultant IF intensities from the combined labeling of the two antibodies clearly show efficacy of administrating everolimus.” The legend of Supplementary Figure 5 “(b) Western blot expression with ponceau S solution showing the total protein. The expression of black band at 46 kDa in western blot represents the amount of pho-GSK3? protein. (c) Western bolt expression of LKB1 for cell lines. The expression of black band at 54 kDa in western blot represents the amount of target protein.” Should read: “(b) Western blot expressions with ponceau S solution showing the total protein. The expressions of black band at 46 kDa in western blot represent the amount of pho-GSK3? protein. (c) Western bolt expressions of LKB1 for cell lines. The expressions of black band at 54 kDa in western blot represents the amount of target protein.”. ? 2020, The Author(s).